Ascelia Pharma plunges again as FDA upholds new study demand for Orviglance

Ascelia Pharma shares fell sharply after the FDA reaffirmed its requirement for a new study of Orviglance, the same candidate that triggered a 75% collapse in July. The decision confirms the regulatory setback and prolongs uncertainty over the drug's approval timeline. This is a company-specific event with no broader market implications.